The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
A safety alert has been issued in Australia concerning GLP-1 receptor agonists like Ozempic. The alert highlights a potential connection to suicidal thoughts and a possible reduction in the effectiveness of oral contraceptives.
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
The rise in popularity of weight loss medications such as Ozempic and Mounjaro is significantly impacting both the food industry and the stock market. Eli Lilly, a pharmaceutical company, experienced a surge in valuation after reporting substantial sales increases. These drugs are changing eating patterns and redefining obesity treatment.
Following Novo Nordisk's price reduction for its Wegovy injection, generic drug manufacturers are reassessing their pricing strategies. The move comes amid increasing competition in the weight-loss drug market, with potential impacts on affordability and market share.
A prominent home services company in the UAE has begun delivering weight-loss medications, indicating the sustained popularity of GLP-1 drugs. This move raises discussions about accessibility and safety when obtaining prescription drugs online.
A new generation of weight loss medications is emerging, promising to be even more effective for human health. These include pills, more powerful injectables, and novel compounds that may have reduced side effects or require only monthly administration.
Indian drugmakers are modifying their pricing strategies for weight-loss injections after Novo Nordisk decreased the price of Wegovy. Generic companies are now reassessing their launch prices due to this shift. Competition is anticipated to lower prices in the GLP-1 market.
